FDA Greenlights Next-Generation ROS1 Inhibitor for Lung Cancer

FDA Greenlights Next-Generation ROS1 Inhibitor for Lung Cancer

(MedPage Today) -- The FDA approved zidesamtinib (Jideytro) for previously treated adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC), drugmaker GSK announced Wednesday. Zidesamtinib is a next-generation...

Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer

/PRNewswire/ -- GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Jideytro (zidesamtinib), a ROS1 selective...

FDA Greenlights GSK’s First Lung Cancer Drug Ahead of Schedule - GSK (NYSE:GSK)

GSK wins early FDA approval for Jideytro, a targeted treatment for adults with advanced ROS1-positive non-small cell lung cancer.

GSK enters lung cancer drug market with early FDA nod for Jideytro

GSK wins US approval for ROS1 lung cancer therapy

Jideytro offers option for previously treated patients

FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC

Findings from the global, single-arm phase 1/2 ARROS-1 trial in patients with advanced or metastatic ROS1-positive NSCLC support the regulatory decision.